Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (“Mindray”) (300760.SZ), a leading global provider of medical devices and solutions, has completed its previously announced acquisition of HyTest Invest Oy and its subsidiaries (“HyTest”), a global leading provider of antibodies and antigens.

“Closing the acquisition of HyTest enables us to have top-notch raw material R&D and innovation capabilities.” said WU Hao, President of Mindray. “We expect HyTest to invest additional resources to continuous development of technologies and products as well as advance technological innovation and academic exploration. We will support HyTest to keep investing in R&D as well as strengthen and improve its key competitive edge, and to maintain its position as a global leader in the upstream IVD raw material business.”

HyTest is a global leading provider of antibodies and antigens focused on IVD market. HyTest has extensive expertise in antibody and antigen design, innovation and production. The company has gained market leading positions in several key segments, including cardiac markers, inflammation, tumor markers and infectious diseases etc. In 2004, HyTest’s cardiac troponin complex material was chosen by AACC as a raw material for the international troponin standard.

About Mindray
Mindray is a leading high-tech medical device manufacturer, and one of the global leaders in medical innovation. The company’s business covers patient monitor & life support, In-vitro diagnostics and medical imaging system. Mindray is committed to create customer value with comprehensive solutions through cutting-edge technological innovation, improving medical conditions and efficiency. For more information on Mindray, visit www.mindray.com

Download the Letter to Partners here.